Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study

Fig. 4

a CNS TTP in patients with symptomatic and asymptomatic BM in cohort 1. CNS TTP for patients with symptomatic BM and patients with asymptomatic BM in cohort 1was NE vs NE, p = 0.394, HR = 3.1(95% CI: 0.12 to 79.0). b CNS TTP in patients with symptomatic and asymptomatic BM in cohort 2. CNS TTP for patients with symptomatic BM and patients with asymptomatic BM in cohort 2 was 21.5 m vs NE, p = 0.168, HR = 2.24 (95% CI: 0.65 to 7.7)

Back to article page